Clinical Trials Logo

Dengue Virus clinical trials

View clinical trials related to Dengue Virus.

Filter by:

NCT ID: NCT00788151 Completed - Dengue Fever Clinical Trials

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Start date: September 26, 2008
Phase: Phase 2
Study type: Interventional

The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: - To describe the humoral immune response to dengue before and after each vaccination with dengue vaccine in two age cohorts of children (6 to 11 years and 2 to 5 years) previously vaccinated with yellow fever (YF) vaccine. - To evaluate the safety of each vaccination with dengue vaccine in two age cohorts of children (6 to 11 years and 2 to 5 years). - To describe viremia after the first and second vaccinations with dengue vaccine in a subgroup of 130 randomized participants (100 participants in Dengue Vaccine Group and 30 participants in Control Group) in two age cohorts of children (6 to 11 years and 2 to 5 years).

NCT ID: NCT00740155 Completed - Dengue Fever Clinical Trials

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

Start date: August 2008
Phase: Phase 2
Study type: Interventional

This is part of an ongoing effort to develop a satisfactory dengue vaccine: Primary objective: To describe the safety after each vaccination with bivalent and tetravalent formulations of dengue vaccine candidates. To describe the immune response after each vaccination of dengue vaccine.

NCT ID: NCT00730288 Completed - Dengue Clinical Trials

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Start date: August 2006
Phase: Phase 2
Study type: Interventional

To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the ChimeriVax™ dengue tetravalent vaccine Primary Objectives: - To describe the safety of one injection of ChimeriVax™ dengue tetravalent vaccine. - To describe the immune response against dengue before and after one injection of ChimeriVax™ dengue tetravalent vaccine

NCT ID: NCT00617344 Completed - Dengue Fever Clinical Trials

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Start date: April 17, 2008
Phase: Phase 2
Study type: Interventional

This study used 3 different formulations of tetravalent CYD dengue vaccine. The primary objective of the study was to evaluate the neutralizing antibody response after 2 doses of two different formulations of tetravalent dengue vaccine administered at Month 0 and Month 6. The secondary objectives were: - To evaluate the safety of the 3 formulations of tetravalent CYD dengue vaccine. - To describe the neutralizing antibody responses to each of the 3 vaccine formulations. - To describe vaccine viremia after the first and second dose of each of the 3 vaccine formulations in a subset of participants.